

DAFTAR PUSTAKA

- Alifieris, C., & Trafalis, D. T. (2015). Glioblastoma multiforme: Pathogenesis and treatment. *Pharmacology Therapy*, 152, 63-82. <https://doi.org/doi:10.1016/j.pharmthera.2015.05.005>. Epub 2015 May 2.
- Ardhini, R., & Tugasworo, D. (2019). Epidemiology of primary brain tumors in dr. Kariadi Hospital Semarang in 2015-2018. The 4th International Conference on Energy, Environment, Epidemiology and Information System,
- Barami, K., Lyon, L., & Conell, C. (2017). Type 2 Diabetes Mellitus and Glioblastoma Multiforme-Assessing Risk and Survival: Results of a Large Retrospective Study and Systematic Review of the Literature. *World Neurosurgery*, 106, 300-307. <https://doi.org/doi:10.1016/j.wneu.2017.06.164>.
- Bent, M. v. d. (2022). *Treatment and Prognosis of IDH-Mutan,1p/19q-Codeleted Oligodendrogliomas in Adults*. Wolters Kluwer. <https://www.uptodate.com/contents/treatment-and-prognosis-of-idh-mutant-1p-19q-codeleted-oligodendrogliomas-in-adults>
- Bernstock, J. D., Gary, S. E., Klinger, N., Valdes, P. A., Essayed, W. I., Olsen, H. E., Chagoya, G., Elsayed, G., Yamashita, D., Schuss, P., Gessler, F. A., Peruzzi, P. P., Bag, A. K., & Friedman, G. K. (2022). Standard clinical approaches and emerging modalities for glioblastoma imaging. *Neuro-oncology Advances*, 4(1), vdac080. <https://doi.org/doi:10.1093/noajnl/vdac080>
- Blionas, A., Giakoumettis, D., Klonou, A., Neromyliotis, E., Karydakakis, P., & Themistocleous, M. S. (2018). Paediatric gliomas: diagnosis, molecular biology and management. 6(12), 251. <https://doi.org/doi:10.21037/atm.2018.05.11>
- Chen, W., Wang, D., Du, X., He, Y., Chen, S., Shao, Q., Ma, C., Huang, B., Chen, A., Zhao, P., Qu, X., & Li, X. (2015). Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes. *Medical Oncology*, 32, 43. <https://doi.org/https://doi.org/10.1007/s12032-015-0487-0>
- Coffey, R. J., Lunsford, L. D., & Taylor, F. H. (1988). Survival after stereotactic biopsy of malignant gliomas. *Neurosurgery*, 22(3), 465-473. <https://doi.org/doi:10.1227/00006123-198803000-00003>.
- Dahlan, M. S. (2011). *Besar sampel dan cara pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*. Salemba Empat. <https://lib.ui.ac.id/m/detail.jsp?id=20449132&lokasi=lokal>
- Daniels, T. B., Brown, P. D., Felten, S. J., Wu, W., Buckner, J. C., Arusell, R. M., Curran, W. J., Abrams, R. A., Schiff, D., & Shaw, E. G. (2011). Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. *International journal of radiation oncology, biology, physics*, 81(1), 218-224. <https://doi.org/doi:10.1016/j.ijrobp.2010.05.003>.

- Decker, M., Sacks, P., Abbatematteo, J., Leo, E. D., Brennan, M., & Rahman, M. (2019). The effects of hyperglycemia on outcomes in surgical high-grade glioma patients. *Clinical neurology and neurosurgery*, 179, 9-13. <https://doi.org/https://doi.org/10.1016/j.clineuro.2019.02.011>
- Deighton, R. F., McGregor, R., Kemp, J., McCulloch, J., & Whittle, I. R. (2010). Glioma Pathophysiology: Insights Emerging from Proteomics. *Brain Pathology*, 20(10), 691-703. <https://doi.org/> <https://doi.org/10.1111/j.1750-3639.2010.00376.x>
- Dietrich, J. (2022). *Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas*. Wolters Kluwer. Retrieved 4th May from <https://medilib.ir/uptodate/show/5228>
- Dietrich, J., Rao, K., Pastorino, S., & Kesari, S. (2011). Corticosteroids in brain cancer patients: benefits and pitfalls. *Expert review of clinical pharmacology*, 4(2), 233-242. <https://doi.org/doi:10.1586/ecp.11.1>
- Drappatz, J. (2021). *Management of vasogenic edema in patients with primary and metastatic brain tumors*. Wolters Kluwer. Retrieved 5th May from <https://medilib.ir/uptodate/show/5182>
- Egan, K. M., Thompson, R. C., Nabors, L. B., Olson, J. J., Brat, D. J., Larocca, R. V., Brem, S., Moots, P. L., Madden, M. H., Browning, J. E., & Chen, Y. A. (2011). Cancer susceptibility variants and the risk of adult glioma in a US case-control study. *Journal of neuro-oncology*, 104(2), 535-542. <https://doi.org/doi:10.1007/s11060-010-0506-0>
- Essayed, W. I., Zhang, F., Unadkat, P., Cosgrove, G. R., Golby, A. J., & O'Donnell, L. J. (2017). White matter tractography for neurosurgical planning: A topography-based review of the current state of the art. *Neuroimage Clinical*, 15, 659-672. <https://doi.org/doi:10.1016/j.nicl.2017.06.011>
- Evans, D. G., & Hanson, H. (2021). *Li-Fraumeni Syndrome*. Wolters Kluwer. Retrieved 5th May from https://www.uptodate.com/contents/li-fraumeni-syndrome?search=li%20fraumeni&source=search_result&selectedTitle=1~60&usage_type=default&display_%20rank=1#topicContent
- Fouke, S. J., Benzinger, T., Gibson, D., Ryken, T. C., Kalkanis, S. N., & Olson, J. J. (2015). The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. *125(3)*, 457-479. <https://doi.org/doi:10.1007/s11060-015-1908-9>
- Gandham, E., D'Souza, W., Mahasampath, G., Moorthy, R., & Rajshekhar, V. (2021). Prognostic significance of modified Pignatti score in patients with World Health Organization grade II diffuse astrocytomas. *International Journal of Neurooncology*, 4(2), 29. https://doi.org/DOI:10.4103/ijno.ijno_9_21
- Gladson, C. L., Prayson, R. A., & Liu, W. (2010). The Pathobiology of Glioma Tumors. *Annual review of pathology*, 5, 33-50. <https://doi.org/doi:10.1146/annurev-pathol-121808-102109>
- Hayat, M. A. (2010). Tumors of the Central Nervous System. *Neuromethods*, 3.

- Ishikawa, T., Muragaki, Y., Maruyama, T., Abe, K., & Kawamata, T. (2017). Roles of the Wada Test and Functional Magnetic Resonance Imaging in Identifying the Language-dominant Hemisphere among Patients with Gliomas Located near Speech Areas. *Neurologia medico-chirurgica*, 57(1), 28-34. <https://doi.org/doi:10.2176/nmc.oa.2016-0042>.
- Jenkins, R. B., Wrensch, M. R., Johnson, D., Fridley, B. L., Decker, P. A., Xiao, Y., Kollmeyer, T. M., Rynearson, A. L., Fink, S., Rice, T., McCoy, L. S., Halder, C., Kosel, M. L., Giannini, C., Tihan, T., O'Neill, B. P., Lachance, D. H., Yang, P., Wiemels, J., & Wiencke, J. K. (2011). Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. *Cancer genetics*, 204(1), 13-18. <https://doi.org/doi:10.1016/j.cancergencyto.2010.10.002>.
- Ji, M., Qi, Q., Wu, K., Lai, Y., Yang, H., & Ma, H. (2023). Incidence, Mortality, Risk factors and Trend analysis of gliomas. *Research Square*. <https://doi.org/https://doi.org/10.21203/rs.3.rs-3177108/v1>
- Jia, Z., Li, X., Yan, Y., Shen, X., Wang, J., Yang, H., Liu, S., Han, C., & Hu, Y. (2022). Exploring the relationship between age and prognosis in glioma: rethinking current age stratification. *BMC neurology*, 22, 350. <https://doi.org/doi:10.1186/s12883-022-02879-9>
- Jungk, C., Gluszak, M., Trong, P. D., Deimling, A. v., Herold-Mende, C., & Unterberg, A. (2021). NCOG-25. REVISITING THE PIGNATTI RISK SCORE IN LOW-GRADE GLIOMA PATIENTS IN THE MOLECULAR ERA. *Neuro-Oncology*, 23 (Supplement 6), vi157. <https://doi.org/DOI:10.1093/neuonc/noab196.616>
- KANYILMAZ, G., ÖNDER, H., AKTAN, M., KOÇ, M., BORA, H., KARAHACIOĞLU, E., ERKAL, H. Ş., & ERKAL, E. Y. (2018). Prognostic Importance of Ki-67 Labeling Index in Grade II Glial Tumors. *TURKISH JOURNAL of ONCOLOGY*, 33(2), 48-53. <https://doi.org/doi:10.5505/tjo.2018.1752>
- Kapoor, M., & Gupta, V. (2023). *Astrocytoma*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK559042/>
- Kim, M., Ladomersky, E., Moznay, A., Kocherginsky, M., O'Shea, K., Reinstein, Z. Z., Lijie Zhai, A. B., Lauing, K. L., Bollu, L., Rabin, E., Dixit, K., Kumthekar, P., Plataniias, L. C., Hou, L., Zheng, Y., Wu, J., Zhang, B., Hrachova, M., Merrill, S. A.,... Wainwright, D. A. (2021). Glioblastoma as an age-related neurological disorder in adults. *Neuro-oncology Advances*, 3(1), vdab125. <https://doi.org/doi:10.1093/noajnl/vdab125>
- Kreth, F. W., Faist, M., Rossner, R., Volk, B., & Ostertag, C. B. (1997). Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. *Cancer genetics*, 79(2), 370-379. [https://doi.org/doi:10.1002/\(sici\)1097-0142\(19970115\)79:2<370::aid-cncr21>3.0.co;2-x](https://doi.org/doi:10.1002/(sici)1097-0142(19970115)79:2<370::aid-cncr21>3.0.co;2-x).

- Krivosheya, D., Prabhu, S. S., Weinberg, J. S., & Sawaya, R. (2016). Technical principles in glioma surgery and preoperative considerations. *Journal of neuro-oncology*, 120(2), 243-252. <https://doi.org/doi: 10.1007/s11060-016-2171-4>.
- Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., Hess, K., Michael, C., Miller, D., & Sawaya, R. (2001). A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. *Journal of Neurosurgery*, 95(2), 190-198. <https://doi.org/doi: 10.3171/jns.2001.95.2.0190>.
- Lanese, A., Franceschi, E., & Brandes, A. A. (2018). The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria. *Oncology Therapy*, 6(2). <https://doi.org/doi: 10.1007/s40487-018-0063-9>.
- Law, M., Yang, S., Wang, H., Babb, J. S., Johnson, G., Cha, S., Knopp, E. A., & Zagzag, D. (2003). Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. *American journal of neuroradiology*, 24(10), 1989-1998. <https://pubmed.ncbi.nlm.nih.gov/14625221/>
- Lote, K., Egeland, T., Hager, B., Stenwig, B., Skullerud, K., Berg-Johnsen, J., Storm-Mathisen, I., & Hirschberg, H. (1997). Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. *Journal of clinical oncology*, 15(9), 3129-3140. <https://doi.org/DOI: 10.1200/JCO.1997.15.9.3129>
- Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., Soffietti, R., Deimling, A. v., & Ellison, D. W. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro-Oncology*, 23(8), 1231-1251. <https://doi.org/doi: 10.1093/neuonc/noab106>.
- Malueka, R. G., Dwianingsih, E. K., Bayuangga, H. F., Panggabean, A. S., Argo, I. W., Donurizki, A. D., Shaleh, S., Wicaksono, A. S., Dananjoyo, K., Asmedi, A., & Hartanto, R. A. (2020). Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population. *Asian Pacific Journal of Cancer Prevention*, 21(8), 2287-2295. <https://doi.org/doi: 10.31557/APJCP.2020.21.8.2287>
- Mayer, A., Vaupel, P., Struss, H.-G., Giese, A., Stockinger, M., & Schmidberger, H. (2014). Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme. *Strahlentherapie und Onkologie*, 190(10), 933-938. <https://doi.org/doi: 10.1007/s00066-014-0696-z>.
- Mesfin, F. B., Karsonovich, T., & Al-Dhahir, M. A. (2022). *Glioma*. StatPearls Publishing.

- Mesfin, F. B., Karsonovich, T., & Al-Dhahir, M. A. (2023). *Glioma*. StatPearls Publishing.
- Michaud, D., & Batchelor, T. (2021). *Risk Factors for Brain Tumors*. Wolters Kluwer. Retrieved 5th May from <https://www.uptodate.com/contents/risk-factors-for-brain-tumors>
- Mukasa, A., Takayanagi, S., Saito, K., Shibahara, J., Tabei, Y., Furuya, K., Ide, T., Narita, Y., Nishikawa, R., Ueki, K., & Saito, N. (2012). Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. *Cancer science*, 103(3), 587-592. <https://doi.org/doi: 10.1111/j.1349-7006.2011.02175.x>
- Musicco, M., Sant, M., Molinari, S., Filippini, G., Gatta, G., & Berrino, F. (1988). A case-control study of brain gliomas and occupational exposure to chemical carcinogens: the risk to farmers. *American journal of epidemiology*, 128(4), 778-785. <https://doi.org/doi: 10.1093/oxfordjournals.aje.a115031>.
- Network, N. C. C. (2022). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. In: National Comprehensive Cancer Network.
- Onder, H., Kanyilmaz, G., Aktan, M., & Karahacioglu, E. (2018). Prognostic factors for survival in adult patients with grade II glial tumors. *Journal of Turgut Ozal Medical Center*, 25(1), 105-111. <https://doi.org/DOI:10.5455/jtomc.2017.12.151>
- Onizuka, H., Masui, K., & Komori, T. (2020). Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System. *International Journal of Clinical Oncology*, 25, 997-1003. <https://doi.org/https://doi.org/10.1007/s10147-020-01695-w>
- Ono, Y., Chernov, M., Muragaki, Y., Maruyama, T., Abe, K., & Iseki, H. (2018). Imaging of Intracranial Gliomas. *Progress in Neurological Surgery*, 30, 12-62. <https://doi.org/DOI:10.1159/000464376>
- Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J. A., Turner, M. C., Walsh, K. M., Wrensch, M. R., & Barnholtz-Sloan, J. S. (2014). The epidemiology of glioma in adults: a “state of the science” review. *Neuro-Oncology*, 16(7), 896-913. <https://doi.org/https://doi.org/10.1093/neuonc/nou087>
- Parastuta, I., Sriwidayani, N., Ekawati, N., & Saputra, H. (2020). Gambaran Klinikopatologi Tumor Glia Tahun 2014-2018 Di Rsup Sanglah Denpasar. *Cerebellum*, 10(11), 9.
- Pérez, I. F., Valverde, D., Valverde, C. F., Iglesias, J. B., Silva, M. J. V., Quintela, M. L., & Meléndez, B. (2022). An analysis of prognostic factors in a cohort of low-grade gliomas and degree of consistency between RTOG and EORTC scores. *Scientific Reports*, 12, 16433. <https://doi.org/https://doi.org/10.1038/s41598-022-20429-8>
- PERMATASARI, E. A., Malueka, R. G., & Dwianingsih, E. K. (2018). Hubungan Mutasi Gen Isocitrate Dehydrogenase (IDH) dengan Nilai Karnofsky

- Performance Scale pada Pasien Glioma di Indonesia. *Repository UGM*.
<https://etd.repository.ugm.ac.id/penelitian/detail/157479>
- Pignatti, F., Bent, M. v. d., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Afra, D., Cornu, P., Bolla, M., Vecht, C., Karim, A. B. M. F., & Group, E. O. f. R. a. T. o. C. B. T. C. G. E. O. f. R. a. T. o. C. R. C. (2002). Prognostic factors for survival in adult patients with cerebral low-grade glioma. *Journal of clinical oncology*, 20(8), 2076-2084. <https://doi.org/doi: 10.1200/JCO.2002.08.121>.
- Pourzitaki, C., Tsaousi, G., Apostolidou, E., Karakoulas, K., Kouvelas, D., & Amaniti, E. (2016). Efficacy and safety of prophylactic levetiracetam in supratentorial brain tumour surgery: a systematic review and meta-analysis. *British journal of clinical pharmacology*, 82(1), 315-325. <https://doi.org/doi: 10.1111/bcp.12926>.
- Price, S., Patel, K., & Narayanan, V. (2012). High grade gliomas: Pathogenesis, management and prognosis. *Advances in Clinical Neuroscience and Rehabilitation*. <https://doi.org/https://doi.org/10.47795/TDQU7727>
- Qi, Z.-Y., Shao, C., Yang, C., Wang, Z., & Hui, G.-Z. (2014). Alcohol Consumption and Risk of Glioma: A Meta-Analysis of 19 Observational Studies. *Nutrients*, 6(2), 504-516. <https://doi.org/doi: 10.3390/nu6020504>
- Rajesh, Y., Pal, I., Banik, P., Chakraborty, S., Borkar, S. A., Dey, G., Mukherjee, A., & Mandal, M. (2017). Insights into molecular therapy of glioma: current challenges and next generation blueprint. *Acta pharmacologica Sinica*, 38(5), 591-613. <https://doi.org/doi: 10.1038/aps.2016.167>
- Rasmussen, B. K., Hansen, S., Laursen, R. J., Kosteljanetz, M., Schultz, H., Nørgård, B. M., Guldberg, R., & Gradel, K. O. (2017). Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. *Journal of neuro-oncology*, 135(3), 571-579. <https://doi.org/doi: 10.1007/s11060-017-2607-5>
- Rathore, S., Chaddad, A., Iftikhar, M. A., Bilello, M., & Abdulkadir, A. (2021). Combining MRI and Histologic Imaging Features for Predicting Overall Survival in Patients with Glioma. *Radiology. Imaging cancer*, 3(4), e200108. <https://doi.org/doi: 10.1148/rycan.2021200108>.
- Recht, L. D., Bent, M. v. d., & Shih, H. A. (2022). *Treatment and prognosis of IDH-mutant astrocytomas in adults*. Wolters Kluwer. <https://www.uptodate.com/contents/treatment-and-prognosis-of-idh-mutant-astrocytomas-in-adults>
- Rudà, R., Capper, D., Waldman, A. D., Pallud, J., Minniti, G., Kaley, T. J., Bouffet, E., Tabatabai, G., Aronica, E., Jakola, A. S., Pfister, S. M., Schiff, D., Lassman, A. B., Solomon, D. A., Soffietti, R., Weller, M., Preusser, M., Idhah, A., Wen, P. Y., & Bent, M. J. v. d. (2022). EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. *Neuro-Oncology*, 24(12), 2015-2034. <https://doi.org/https://doi.org/10.1093/neuonc/noac188>
- Rudà, R., Pellerino, A., Magistrello, M., Franchino, F., & Soffietti, R. (2015). Molecularly based management of gliomas in clinical practice. *Neurological*

- Science*, 36, 1551-1557. <https://doi.org/https://doi.org/10.1007/s10072-015-2332-9>
- Scerrati, M., Roselli, R., Iacoangeli, M., Pompucci, A., & Rossi, G. F. (1996). Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres: the role of surgery. *Journal of neurology, neurosurgery, and psychiatry*, 61(3), 291-296. <https://doi.org/doi: 10.1136/jnnp.61.3.291>.
- Sharma, A., & Graber, J. J. (2021). Overview of prognostic factors in adult gliomas. *Annals of Palliative Medicine*, 10(1), 863-874. <https://doi.org/doi: 10.21037/apm-20-640>
- Singh, S., Deora, H., Neyaz, A., Das, K. K., Mehrotra, A., Srivastava, A. K., Behari, S., Jaiswal, A. K., & Jaiswal, S. (2021). Trends in clinico-epidemiology profile of surgically operated glioma patients in a tertiary care center over 12 years—through the looking glass! *Egyptian Journal of Neurosurgery*, 36, 32. <https://doi.org/https://doi.org/10.1186/s41984-021-00118-w>
- Skaga, E., Trewin-Nybråten, C. B., Niehusmann, P., Johannesen, T. B., Marienhagen, K., Oltedal, L., Schipman, S., Skjulsvik, A. J., Solheim, O., Solheim, T. S., Sundstrøm, T., Vik-Mo, E. O., Brandal, P., & Ingebrigtsen, T. (2024). Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study. *Acta Oncologica*, 63, 83-94. <https://doi.org/DOI:10.2340/1651-226X.2024.24970>
- Soffietti, R., Trevisan, E., Ruda, R., Bertero, L., Bosa, C., Fabrini, M. G., & Lolli, I. (2011). Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology). *Journal of clinical oncology*, 25(15). https://doi.org/https://doi.org/10.1200/jco.2011.29.15_suppl.2027
- Stark, A. M., Bergh, J. v. d., Hedderich, J., Mehdorn, H. M., & Nabavi, A. (2012). Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. *Clinical neurology and neurosurgery*, 114(7), 840-845. <https://doi.org/DOI: 10.1016/j.clineuro.2012.01.026>
- Stupp, R., Mason, W. P., Bent, M. J. v. d., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., & Mirimanoff, R. O. (2005). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. *The New England Journal of Medicine*, 352, 987-996. <https://doi.org/DOI: 10.1056/NEJMoa043330>
- Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014). Epidemiologic and molecular prognostic review of glioblastoma. *Cancer epidemiology, biomarkers & prevention*, 23(10), 1985–1996. <https://doi.org/doi: 10.1158/1055-9965.EPI-14-0275>
- Tieu, M. T., Lovblom, L. E., McNamara, M. G., Mason, W., Laperriere, N., Millar, B.-A., Ménard, C., Kiehl, T.-R., Perkins, B. A., & Chung, C. (2015). Impact of glycemia on survival of glioblastoma patients treated with radiation and

- temozolomide. *Journal of neuro-oncology*, 124, 119-126. <https://doi.org/https://doi.org/10.1007/s11060-015-1815-0>
- Wainwright, D. A., Balyasnikova, I. V., Chang, A. L., Ahmed, A. U., Moon, K.-S., Auffinger, B., Tobias, A. L., Han, Y., & Lesniak, M. S. (2012). IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. *Clinical cancer research*, 18(22), 6110-6121. <https://doi.org/doi: 10.1158/1078-0432.CCR-12-2130>.
- Wang, L., Babikir, H., Müller, S., Yagnik, G., Shamardani, K., Catalan, F., Kohanbash, G., Alvarado, B., Lullo, E. D., Kriegstein, A., Shah, S., Wadhwa, H., Chang, S. M., Phillips, J. J., Aghi, M. K., & Diaz, A. A. (2019). The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation. *Cancer Discovery*, 9(12), 1708-1719. <https://doi.org/doi: 10.1158/2159-8290.CD-19-0329>.
- Wang, L., Jung, J., Babikir, H., Shamardani, K., Jain, S., Feng, X., Gupta, N., Rosi, S., Chang, S., Raleigh, D., Solomon, D., Phillips, J. J., & Diaz, A. A. (2022). A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. *Nature Science*, 3, 1534–1552. <https://doi.org/https://doi.org/10.1038/s43018-022-00475-x>
- Weller, M., Bent, M. v. d., Preusser, M., Rhun, E. L., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., French, P., Hegi, M. E., Jakola, A. S., Platten, M., Roth, P., Rudà, R., Short, S., Smits, M., Taphoorn, M. J. B.,... Wick, W. (2021). EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nature reviews. Clinical oncology*, 18(3), 170-186. <https://doi.org/doi: 10.1038/s41571-020-00447-z>.
- Wen, P. Y., & Lee, E. Q. (2018). Neuro-oncology, An Issue of Neurologic Clinics. In *Neuro-Oncology* (1 ed., Vol. 36-3). Elsevier. <https://shop.elsevier.com/books/neuro-oncology-an-issue-of-neurologic-clinics/wen/978-0-323-61402-3>
- Wesseling, P., & Capper, D. (2018). WHO 2016 Classification of gliomas. *Neuropathology and applied neurobiology*, 44(2), 139-150. <https://doi.org/doi: 10.1111/nan.12432>.
- Whitfield, B. T., & Huse, J. T. (2022). Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. *Brain Pathology*, 32(4), e13062. <https://doi.org/doi: 10.1111/bpa.13062>.
- Willman, M., Willman, J., Figg, J., Dioso, E., Sriram, S., Olowofela, B., Chacko, K., Hernandez, J., & Lucke-Wold, B. (2023). Update for astrocytomas: medical and surgical management considerations. *Explore Neuroscience*, 2, 1-26. <https://doi.org/DOI: https://doi.org/10.37349/en.2023.00009>